Ocular phenotype and therapeutic interventions in keratitis-ichthyosis-deafness (KID) syndrome
Authors:
- 27 September 2023
- journal article
- research article
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 45 (1) , 16-22
Abstract
To report ocular manifestations, clinical course, and therapeutic management of patients with molecular genetically confirmed keratitis-ichthyosis-deafness syndrome. Four patients, aged 19 to 46, with keratitis-ichthyosis-deafness syndrome from across the UK were recruited for a general and ocular examination and GJB2 (Cx26) mutational analysis. The ocular examination included best-corrected visual acuity, slit-lamp bio-microscopy, and ocular surface assessment. Mutational analysis of the coding region of GJB2 (Cx26) was performed by bidirectional Sanger sequencing. All four individuals had the characteristic systemic features of keratitis-ichthyosis-deafness syndrome. Each patient was found to have a missense mutation, resulting in the substitution of aspartic acid with asparagine at codon 50 (p.D50N). Main ophthalmic features were vascularizing keratopathy, ocular surface disease, hyperkeratotic lid lesions, recurrent epithelial defects, and corneal stromal scarring. One patient had multiple surgical procedures, including superficial keratectomies and lamellar keratoplasty, which failed to prevent severe visual loss. In contrast, oral therapy with ketoconazole stabilized the corneal and skin disease in two other patients with keratitis-ichthyosis-deafness syndrome. The patient who underwent intracorneal bevacizumab injection showed a marked reduction in corneal vascularization following a single application. Keratitis-ichthyosis-deafness syndrome is a rare ectodermal dysplasia caused by heterozygous mutations in GJB2 (Cx26) with a severe, progressive vascularizing keratopathy. Oral ketoconazole therapy may offer benefit in stabilizing the corneal and skin disease.Keywords
Funding Information
- no funding associated
This publication has 29 references indexed in Scilit:
- Corneal endothelial safety following subconjunctival and intrastromal injection of bevacizumab for corneal neovascularizationInternational Ophthalmology, 2013
- Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trialBritish Journal of Ophthalmology, 2012
- Topical Bevacizumab in the Treatment of Corneal NeovascularizationArchives of Ophthalmology (1950), 2009
- Ocular manifestations of keratitis– ichthyosis–deafness (KID) syndromeOphthalmology, 2005
- A Novel Connexin 26 Mutation in a Patient Diagnosed with Keratitis–Ichthyosis–Deafness SyndromeJournal of Investigative Dermatology, 2002
- Keratitis, Ichthyosis, and Deafness (KID Syndrome): Review of the Literature and Proposal of a New TerminologyPediatric Dermatology, 1996
- KERATITIS, ICHTHYOSIS, AND DEAFNESS (KID) SYNDROME: MANAGEMENT WITH CHRONIC ORAL KETOCONAZOLE THERAPYInternational Journal of Dermatology, 1992
- The Use of Ketoconazole as an Inhibitor of Steroid ProductionNew England Journal of Medicine, 1987
- Ketoconazole—an oral antifungal with activity against superficial and deep mycosesJournal of the American Academy of Dermatology, 1980
- Atypical ichthyosiform erythroderma, deafness and keratitis.British Journal of Dermatology, 1976